Amring Pharms Drug Patent Portfolio

Amring Pharms owns 1 orange book drug protected by 8 US patents Given below is the list of Amring Pharms's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7947739 Tranexamic acid formulations 04 Mar, 2025
Active
US8022106 Tranexamic acid formulations 04 Mar, 2025
Active
US8273795 Tranexamic acid formulations 04 Mar, 2025
Active
US8487005 Tranexamic acid formulations 04 Mar, 2025
Active
US8791160 Tranexamic acid formulations 04 Mar, 2025
Active
US8809394 Tranexamic acid formulations 04 Mar, 2025
Active
US8957113 Tranexamic acid formulations 04 Mar, 2025
Active
US9060939 Tranexamic acid formulations 04 Mar, 2025
Active


Given below is the list of recent legal activities going on the following drug patents of Amring Pharms.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 17 Nov, 2023 US8273795
Payment of Maintenance Fee, 12th Year, Large Entity 04 Nov, 2022 US8022106 (Litigated)
Correspondence Address Change 18 Oct, 2022 US8022106 (Litigated)
Correspondence Address Change 18 Oct, 2022 US8273795
Correspondence Address Change 18 Oct, 2022 US8809394
Correspondence Address Change 18 Oct, 2022 US8791160
Correspondence Address Change 18 Oct, 2022 US9060939
Correspondence Address Change 18 Oct, 2022 US8487005
Payment of Maintenance Fee, 8th Year, Large Entity 16 Aug, 2022 US9060939
Payment of Maintenance Fee, 12th Year, Large Entity 16 Aug, 2022 US7947739
Payment of Maintenance Fee, 8th Year, Large Entity 06 Jan, 2022 US8791160
Payment of Maintenance Fee, 8th Year, Large Entity 06 Jan, 2022 US8809394
Payment of Maintenance Fee, 8th Year, Large Entity 05 Jan, 2021 US8487005
Payment of Maintenance Fee, 8th Year, Large Entity 19 Mar, 2020 US8273795
Payment of Maintenance Fee, 8th Year, Large Entity 12 Mar, 2019 US8022106 (Litigated)


Amring Pharms's Family Patents

Amring Pharms drugs have patent protection in a total of 2 countries. It has a significant patent presence in the US with 82.6% of its patents being US patents. Click below to unlock the full patent family tree.

Family Patents



Amring Pharms Drug List

Given below is the complete list of Amring Pharms's drugs and the patents protecting them.


1. Lysteda

Lysteda is protected by 8 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7947739 Tranexamic acid formulations 04 Mar, 2025
(2 months from now)
Active
US8022106 Tranexamic acid formulations 04 Mar, 2025
(2 months from now)
Active
US8273795 Tranexamic acid formulations 04 Mar, 2025
(2 months from now)
Active
US8487005 Tranexamic acid formulations 04 Mar, 2025
(2 months from now)
Active
US8791160 Tranexamic acid formulations 04 Mar, 2025
(2 months from now)
Active
US8809394 Tranexamic acid formulations 04 Mar, 2025
(2 months from now)
Active
US8957113 Tranexamic acid formulations 04 Mar, 2025
(2 months from now)
Active
US9060939 Tranexamic acid formulations 04 Mar, 2025
(2 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lysteda's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List